News about investigational drugs, which are expected to make big differences in the lives of people with chronic diseases and deadly diseases does not always materialize. Predicting drugs becoming breakthroughs has proven extremely difficult in the early phases of drugs’ development. Some products keep doing well, going from the preclinical testing into several phases of trials then all of a sudden they unexpectedly fail. They disappoint the scientists who created them, the firms that adapted the hypothesis that formed the basis of the drug’s production and the positive analysts highly recommended them.

Some products’ results, however, look so good . . .